Xellia signs distribution agreement on five generic drugs Danish pharmaceutical company Xellia Pharmaceuticals has signed a distribution agreement with Indian Caplin Point Laboratories that allows Xellia to commercialize five generic drugs in the US. Photo: Xellia Pharmaceuticals / PR BY KEVIN GRØNNEMANN, TRANSLATED BY IDA LØJMAND Published: 08.07.20 at 10:23 Share by email Share on LinkedIn Share on Facebook Share on Twitter Log in to read our articles Welcome to MedWatch. A part of our content is exclusive and reserved for our users. Log in Try MedWatch for 14 days. Get a trial subscription here. Do you want a trial subscription with multiple users for yourself and your colleagues? Read more about your options and find the contact information to our sales team here. Print Print Increase text size Increase text size Decrease text size Decrease text size Related articles Xellia lands record profit of DKK 440 million (USD 64.5 million) - revenue increases by 15 percent.